Market Research

Global Actinic Keratosis Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class, By Therapy (Surgery, Topical and Photodynamic Therapy), By End-use (Hospitals, Private Clinics, Homecare and Others), By Regional Outlook and Forecast,

Best Price Guarantee Length Publisher Published Date SKU
from $3,600 224 Pages Knowledge Based Value (KBV) Research November, 2022 KBV17582876
Best Price Guarantee
Price from $3,600
Length 224 Pages
Publisher Knowledge Based Value (KBV) Research
Published Date November, 2022
SKU KBV17582876

Global Actinic Keratosis Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class, By Therapy (Surgery, Topical and Photodynamic Therapy), By End-use (Hospitals, Private Clinics, Homecare and Others), By Regional Outlook and Forecast, 2022 - 2028

The Global Actinic Keratosis Treatment Market size is expected to reach $8 billion by 2028, rising at a market growth of 4.4% CAGR during the forecast period.

Actinic keratosis is the most frequent precancer that develops on skin that has been chronically damaged by ultraviolet rays emitted by the sun or/and indoor tanning. This disorder is also referred to as solar keratosis. If someone already has an AK, they are more likely to go on to acquire further actinic keratoses. Since AKs can turn into squamous cell carcinoma (SCC), a frequent and occasionally invasive form of the illness, this increases the risk of developing skin cancer.

Squamous cells, one of the three primary cell types in the epidermis, are flat cells close to the skin's surface that continuously shed as new ones develop. Squamous cell carcinoma (SCC) develops when aberrant squamous cell alterations result from DNA damage brought on by exposure to UV radiation or other harmful factors. SCCs can manifest as elevated developments with a central depression, open sores, scaly red patches, and rough, thickened, or wart-like skin. SCCs can develop in various additional body parts, including the genitalia.

The skin precancer actinic keratosis is quite widespread. Knowing the risk factors and the causes of AK can assist individuals to stop it from happening. It is easier for people to identify AKs early on when they are very curable if they are aware of the disease risk. Sun exposure causes cumulative skin damage. This implies that the risk of developing AKs increases the longer people stay in the sun over time, even for small durations.

This includes persons who work outside in the sunlight, those who have thinning hair or a bald head, and those with sunburns. The UV rays that indoor tanning beds emit are particularly hazardous since they increase the risk of getting AKs and other forms of skin cancer. More people are exposed to the damaging effects of the sun when they live near the equator where UV rays are high for most of the year. Therefore, those who reside in areas near the equator have a higher chance of developing AKs.

COVID-19 Impact Analysis

A significant slowdown in the supply chain, stock market volatility, deterioration in corporate morale, and rising public confusion and fear about the future are just a few of the many effects of the COVID-19 pandemic. On the actinic keratosis treatments market, the pandemic had a negative effect. Diagnose and treatment rates were significantly lower as a result of total lockdown in the majority of nations and restrictions on non-essential doctor visits. Additionally, most hospitals maintained ongoing communication with dermatologists to reduce the number of patients who visited with actinic keratosis and other non-urgent medical issues. However, the market for actinic keratosis treatments is anticipated to rise as COVID-19 limits are loosened across the board.

Market Growth Factors

The Increased Use Of Minimally Invasive Clinical Procedures

There is a high prevalence of actinic keratosis as a consequence of ozone layer degradation and prolonged sun exposure. Increasing cancer cases and a strong desire for minimally invasive (MI) therapies are growing. Actinic keratosis is projected to become more common, and there will also be a greater need for therapies as people become more aware of how to manage their illnesses. The demand for actinic keratosis treatment is rising as people become more aware of its negative effects. Additionally, the frequency of identification and treatment has increased because of the higher risk of developing skin cancer linked to actinic keratosis.

Expanding Government Initiatives To Increase Affordability

The number of patients undergoing actinic keratosis therapy has also been impacted by government initiatives to increase access to and affordability of healthcare facilities. In the coming years, the availability of alluring rebate programs is anticipated to stimulate demand development. Around the world, a number of public and private groups are attempting to increase public knowledge of actinic keratosis treatment options. Furthermore, actinic keratosis treatments are growing along with significant investments in research & development projects to produce novel medications with higher efficacy, convenient dosage, and cheaper pricing.

Market Restraining Factors

Low Treatment Penetration And A Lack Of Qualified Specialists

The most important factor for the treatment of actinic keratosis is an effective method to control and cure it. Research and experiments have shown methods like cryotherapy and photodynamic therapy to be most effective in managing actinic keratosis. But the severe lack of qualified healthcare professionals increases the gap between the growing number of patients and the doctors who can treat it. Even for the treatment of actinic keratosis by chemical peels, qualified medical personnel and surgeons are required.

Therapy Outlook

Based on therapy, the actinic keratosis treatment market is categorized into topical, photodynamic therapy, and surgery. The photodynamic segment witnessed a significant revenue share in the actinic keratosis treatment market in 2021. A non-invasive treatment for photodamage, precancerous spots, and other skin disorders is photodynamic blue light therapy. Aminolevulinic acid, a drug that reacts to light, is applied to the spot being treated. The targeted cells are then obliterated by a blue light that is then focused on the therapy area. Large regions can be effectively treated in this way.

Drug Class Outlook

On the basis of drug class, the actinic keratosis treatment market is divided into nucleoside metabolic inhibitor, NSAIDs, immune response modifiers, photoenhancers, and others. The NSAIDs segment recorded a substantial revenue share in the actinic keratosis treatment market in 2021. Non-steroidal anti-inflammatory medicines (NSAIDs) work by irreversibly or reversibly acetylating COX isoforms, blocking downstream prostaglandins, and possibly acting as chemopreventatives in the case of malignancies like skin cancer.

End-Use Outlook

Based on end-use, the actinic keratosis treatment market is segmented into hospitals, private clinics, homecare, and others. The homecare segment acquired a significant revenue share in the actinic keratosis treatment market in 2021. The increasing usage of topical treatments, patient comfort factors, the accessibility of over-the-counter (OTC) products, and the expanding number of topical product launches are all factors contributing to the expansion of the homecare segment.

Regional Outlook

On the basis of region, the actinic keratosis treatment market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment garnered the highest revenue share in the actinic keratosis treatment market in 2021. Actinic keratosis' increasing incidence, encouraging government measures, more consumer awareness, better healthcare infrastructure improvements, and continued technical breakthroughs are all credited with the rise. One of the main causes of business growth is also the existence of important players in the market in North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Almirall, S.A, LEO Pharma A/S, Biofrontera AG, Sun Pharmaceuticals Industries Ltd., 3M Company, Bausch Health Companies, Inc., Novartis AG, Viatris, Inc., and Galderma S.A.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

  • Nucleoside Metabolic Inhibitor
  • NSAIDs
  • Immune Response Modifiers
  • Photoenhancers
  • Others
By Therapy
  • Surgery
  • Topical
  • Photodynamic Therapy
By End-use
  • Hospitals
  • Private Clinics
  • Homecare
  • Others
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • Almirall, S.A
  • LEO Pharma A/S
  • Biofrontera AG
  • Sun Pharmaceuticals Industries Ltd.
  • 3M Company
  • Bausch Health Companies, Inc.
  • Novartis AG
  • Viatris, Inc.
  • Galderma S.A.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Actinic Keratosis Treatment Market, by Drug Class
1.4.2 Global Actinic Keratosis Treatment Market, by Therapy
1.4.3 Global Actinic Keratosis Treatment Market, by End-use
1.4.4 Global Actinic Keratosis Treatment Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Actinic Keratosis Treatment Market by Drug Class
3.1 Global Nucleoside Metabolic Inhibitor Market by Region
3.2 Global NSAIDs Market by Region
3.3 Global Immune Response Modifiers Market by Region
3.4 Global Photoenhancers Market by Region
3.5 Global Others Market by Region
Chapter 4. Global Actinic Keratosis Treatment Market by Therapy
4.1 Global Surgery Market by Region
4.2 Global Topical Market by Region
4.3 Global Photodynamic Therapy Market by Region
Chapter 5. Global Actinic Keratosis Treatment Market by End-use
5.1 Global Hospitals Market by Region
5.2 Global Private Clinics Market by Region
5.3 Global Homecare Market by Region
5.4 Global Others Market by Region
Chapter 6. Global Actinic Keratosis Treatment Market by Region
6.1 North America Actinic Keratosis Treatment Market
6.1.1 North America Actinic Keratosis Treatment Market by Drug Class
6.1.1.1 North America Nucleoside Metabolic Inhibitor Market by Country
6.1.1.2 North America NSAIDs Market by Country
6.1.1.3 North America Immune Response Modifiers Market by Country
6.1.1.4 North America Photoenhancers Market by Country
6.1.1.5 North America Others Market by Country
6.1.2 North America Actinic Keratosis Treatment Market by Therapy
6.1.2.1 North America Surgery Market by Country
6.1.2.2 North America Topical Market by Country
6.1.2.3 North America Photodynamic Therapy Market by Country
6.1.3 North America Actinic Keratosis Treatment Market by End-use
6.1.3.1 North America Hospitals Market by Country
6.1.3.2 North America Private Clinics Market by Country
6.1.3.3 North America Homecare Market by Country
6.1.3.4 North America Others Market by Country
6.1.4 North America Actinic Keratosis Treatment Market by Country
6.1.4.1 US Actinic Keratosis Treatment Market
6.1.4.1.1 US Actinic Keratosis Treatment Market by Drug Class
6.1.4.1.2 US Actinic Keratosis Treatment Market by Therapy
6.1.4.1.3 US Actinic Keratosis Treatment Market by End-use
6.1.4.2 Canada Actinic Keratosis Treatment Market
6.1.4.2.1 Canada Actinic Keratosis Treatment Market by Drug Class
6.1.4.2.2 Canada Actinic Keratosis Treatment Market by Therapy
6.1.4.2.3 Canada Actinic Keratosis Treatment Market by End-use
6.1.4.3 Mexico Actinic Keratosis Treatment Market
6.1.4.3.1 Mexico Actinic Keratosis Treatment Market by Drug Class
6.1.4.3.2 Mexico Actinic Keratosis Treatment Market by Therapy
6.1.4.3.3 Mexico Actinic Keratosis Treatment Market by End-use
6.1.4.4 Rest of North America Actinic Keratosis Treatment Market
6.1.4.4.1 Rest of North America Actinic Keratosis Treatment Market by Drug Class
6.1.4.4.2 Rest of North America Actinic Keratosis Treatment Market by Therapy
6.1.4.4.3 Rest of North America Actinic Keratosis Treatment Market by End-use
6.2 Europe Actinic Keratosis Treatment Market
6.2.1 Europe Actinic Keratosis Treatment Market by Drug Class
6.2.1.1 Europe Nucleoside Metabolic Inhibitor Market by Country
6.2.1.2 Europe NSAIDs Market by Country
6.2.1.3 Europe Immune Response Modifiers Market by Country
6.2.1.4 Europe Photoenhancers Market by Country
6.2.1.5 Europe Others Market by Country
6.2.2 Europe Actinic Keratosis Treatment Market by Therapy
6.2.2.1 Europe Surgery Market by Country
6.2.2.2 Europe Topical Market by Country
6.2.2.3 Europe Photodynamic Therapy Market by Country
6.2.3 Europe Actinic Keratosis Treatment Market by End-use
6.2.3.1 Europe Hospitals Market by Country
6.2.3.2 Europe Private Clinics Market by Country
6.2.3.3 Europe Homecare Market by Country
6.2.3.4 Europe Others Market by Country
6.2.4 Europe Actinic Keratosis Treatment Market by Country
6.2.4.1 Germany Actinic Keratosis Treatment Market
6.2.4.1.1 Germany Actinic Keratosis Treatment Market by Drug Class
6.2.4.1.2 Germany Actinic Keratosis Treatment Market by Therapy
6.2.4.1.3 Germany Actinic Keratosis Treatment Market by End-use
6.2.4.2 UK Actinic Keratosis Treatment Market
6.2.4.2.1 UK Actinic Keratosis Treatment Market by Drug Class
6.2.4.2.2 UK Actinic Keratosis Treatment Market by Therapy
6.2.4.2.3 UK Actinic Keratosis Treatment Market by End-use
6.2.4.3 France Actinic Keratosis Treatment Market
6.2.4.3.1 France Actinic Keratosis Treatment Market by Drug Class
6.2.4.3.2 France Actinic Keratosis Treatment Market by Therapy
6.2.4.3.3 France Actinic Keratosis Treatment Market by End-use
6.2.4.4 Russia Actinic Keratosis Treatment Market
6.2.4.4.1 Russia Actinic Keratosis Treatment Market by Drug Class
6.2.4.4.2 Russia Actinic Keratosis Treatment Market by Therapy
6.2.4.4.3 Russia Actinic Keratosis Treatment Market by End-use
6.2.4.5 Spain Actinic Keratosis Treatment Market
6.2.4.5.1 Spain Actinic Keratosis Treatment Market by Drug Class
6.2.4.5.2 Spain Actinic Keratosis Treatment Market by Therapy
6.2.4.5.3 Spain Actinic Keratosis Treatment Market by End-use
6.2.4.6 Italy Actinic Keratosis Treatment Market
6.2.4.6.1 Italy Actinic Keratosis Treatment Market by Drug Class
6.2.4.6.2 Italy Actinic Keratosis Treatment Market by Therapy
6.2.4.6.3 Italy Actinic Keratosis Treatment Market by End-use
6.2.4.7 Rest of Europe Actinic Keratosis Treatment Market
6.2.4.7.1 Rest of Europe Actinic Keratosis Treatment Market by Drug Class
6.2.4.7.2 Rest of Europe Actinic Keratosis Treatment Market by Therapy
6.2.4.7.3 Rest of Europe Actinic Keratosis Treatment Market by End-use
6.3 Asia Pacific Actinic Keratosis Treatment Market
6.3.1 Asia Pacific Actinic Keratosis Treatment Market by Drug Class
6.3.1.1 Asia Pacific Nucleoside Metabolic Inhibitor Market by Country
6.3.1.2 Asia Pacific NSAIDs Market by Country
6.3.1.3 Asia Pacific Immune Response Modifiers Market by Country
6.3.1.4 Asia Pacific Photoenhancers Market by Country
6.3.1.5 Asia Pacific Others Market by Country
6.3.2 Asia Pacific Actinic Keratosis Treatment Market by Therapy
6.3.2.1 Asia Pacific Surgery Market by Country
6.3.2.2 Asia Pacific Topical Market by Country
6.3.2.3 Asia Pacific Photodynamic Therapy Market by Country
6.3.3 Asia Pacific Actinic Keratosis Treatment Market by End-use
6.3.3.1 Asia Pacific Hospitals Market by Country
6.3.3.2 Asia Pacific Private Clinics Market by Country
6.3.3.3 Asia Pacific Homecare Market by Country
6.3.3.4 Asia Pacific Others Market by Country
6.3.4 Asia Pacific Actinic Keratosis Treatment Market by Country
6.3.4.1 China Actinic Keratosis Treatment Market
6.3.4.1.1 China Actinic Keratosis Treatment Market by Drug Class
6.3.4.1.2 China Actinic Keratosis Treatment Market by Therapy
6.3.4.1.3 China Actinic Keratosis Treatment Market by End-use
6.3.4.2 Japan Actinic Keratosis Treatment Market
6.3.4.2.1 Japan Actinic Keratosis Treatment Market by Drug Class
6.3.4.2.2 Japan Actinic Keratosis Treatment Market by Therapy
6.3.4.2.3 Japan Actinic Keratosis Treatment Market by End-use
6.3.4.3 India Actinic Keratosis Treatment Market
6.3.4.3.1 India Actinic Keratosis Treatment Market by Drug Class
6.3.4.3.2 India Actinic Keratosis Treatment Market by Therapy
6.3.4.3.3 India Actinic Keratosis Treatment Market by End-use
6.3.4.4 South Korea Actinic Keratosis Treatment Market
6.3.4.4.1 South Korea Actinic Keratosis Treatment Market by Drug Class
6.3.4.4.2 South Korea Actinic Keratosis Treatment Market by Therapy
6.3.4.4.3 South Korea Actinic Keratosis Treatment Market by End-use
6.3.4.5 Singapore Actinic Keratosis Treatment Market
6.3.4.5.1 Singapore Actinic Keratosis Treatment Market by Drug Class
6.3.4.5.2 Singapore Actinic Keratosis Treatment Market by Therapy
6.3.4.5.3 Singapore Actinic Keratosis Treatment Market by End-use
6.3.4.6 Malaysia Actinic Keratosis Treatment Market
6.3.4.6.1 Malaysia Actinic Keratosis Treatment Market by Drug Class
6.3.4.6.2 Malaysia Actinic Keratosis Treatment Market by Therapy
6.3.4.6.3 Malaysia Actinic Keratosis Treatment Market by End-use
6.3.4.7 Rest of Asia Pacific Actinic Keratosis Treatment Market
6.3.4.7.1 Rest of Asia Pacific Actinic Keratosis Treatment Market by Drug Class
6.3.4.7.2 Rest of Asia Pacific Actinic Keratosis Treatment Market by Therapy
6.3.4.7.3 Rest of Asia Pacific Actinic Keratosis Treatment Market by End-use
6.4 LAMEA Actinic Keratosis Treatment Market
6.4.1 LAMEA Actinic Keratosis Treatment Market by Drug Class
6.4.1.1 LAMEA Nucleoside Metabolic Inhibitor Market by Country
6.4.1.2 LAMEA NSAIDs Market by Country
6.4.1.3 LAMEA Immune Response Modifiers Market by Country
6.4.1.4 LAMEA Photoenhancers Market by Country
6.4.1.5 LAMEA Others Market by Country
6.4.2 LAMEA Actinic Keratosis Treatment Market by Therapy
6.4.2.1 LAMEA Surgery Market by Country
6.4.2.2 LAMEA Topical Market by Country
6.4.2.3 LAMEA Photodynamic Therapy Market by Country
6.4.3 LAMEA Actinic Keratosis Treatment Market by End-use
6.4.3.1 LAMEA Hospitals Market by Country
6.4.3.2 LAMEA Private Clinics Market by Country
6.4.3.3 LAMEA Homecare Market by Country
6.4.3.4 LAMEA Others Market by Country
6.4.4 LAMEA Actinic Keratosis Treatment Market by Country
6.4.4.1 Brazil Actinic Keratosis Treatment Market
6.4.4.1.1 Brazil Actinic Keratosis Treatment Market by Drug Class
6.4.4.1.2 Brazil Actinic Keratosis Treatment Market by Therapy
6.4.4.1.3 Brazil Actinic Keratosis Treatment Market by End-use
6.4.4.2 Argentina Actinic Keratosis Treatment Market
6.4.4.2.1 Argentina Actinic Keratosis Treatment Market by Drug Class
6.4.4.2.2 Argentina Actinic Keratosis Treatment Market by Therapy
6.4.4.2.3 Argentina Actinic Keratosis Treatment Market by End-use
6.4.4.3 UAE Actinic Keratosis Treatment Market
6.4.4.3.1 UAE Actinic Keratosis Treatment Market by Drug Class
6.4.4.3.2 UAE Actinic Keratosis Treatment Market by Therapy
6.4.4.3.3 UAE Actinic Keratosis Treatment Market by End-use
6.4.4.4 Saudi Arabia Actinic Keratosis Treatment Market
6.4.4.4.1 Saudi Arabia Actinic Keratosis Treatment Market by Drug Class
6.4.4.4.2 Saudi Arabia Actinic Keratosis Treatment Market by Therapy
6.4.4.4.3 Saudi Arabia Actinic Keratosis Treatment Market by End-use
6.4.4.5 South Africa Actinic Keratosis Treatment Market
6.4.4.5.1 South Africa Actinic Keratosis Treatment Market by Drug Class
6.4.4.5.2 South Africa Actinic Keratosis Treatment Market by Therapy
6.4.4.5.3 South Africa Actinic Keratosis Treatment Market by End-use
6.4.4.6 Nigeria Actinic Keratosis Treatment Market
6.4.4.6.1 Nigeria Actinic Keratosis Treatment Market by Drug Class
6.4.4.6.2 Nigeria Actinic Keratosis Treatment Market by Therapy
6.4.4.6.3 Nigeria Actinic Keratosis Treatment Market by End-use
6.4.4.7 Rest of LAMEA Actinic Keratosis Treatment Market
6.4.4.7.1 Rest of LAMEA Actinic Keratosis Treatment Market by Drug Class
6.4.4.7.2 Rest of LAMEA Actinic Keratosis Treatment Market by Therapy
6.4.4.7.3 Rest of LAMEA Actinic Keratosis Treatment Market by End-use
Chapter 7. Company Profiles
7.1 Almirall, S.A
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.1.5.2 Product Launches and Product Expansions:
7.2 LEO Pharma A/S
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 Biofrontera AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Research & Development Expenses
7.4 Sun Pharmaceuticals Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.5 3M Company
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 SWOT Analysis
7.6 Bausch Health Companies, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Novartis AG
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Viatris, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Galderma S.A.
7.9.1 Company Overview

$3,600
$4,320
$6,048

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings